Taste Note - Amazon Business Biographies Best Sellers
Bad Blood: Theranos and the Anatomy of Governance Failure
A Kurums Book Taste review of Bad Blood for directors, investors, and executives who want to know exactly how a celebrated board missed a $9 billion fraud.
Why this book fits Kurums
Theranos had the most decorated board in startup history - former secretaries of state, senators, four-star officers - and none of it worked, because prestige is not oversight. Carreyrou's reconstruction of how Elizabeth Holmes raised hundreds of millions on blood-testing technology that never functioned is, read from the boardroom, a catalogue of every control that was absent: no audited financials for years, no director with domain expertise, dual-class voting that made supervision decorative, and a culture where questioning data got you escorted out.
For the Kurums Corporate Governance audience the book's value is specificity. Each chapter names the mechanism - secrecy enforced by lawyers, departments siloed so no one saw the whole, auditors and partners placated with demos - and each mechanism has a checklist-ready negation. It is also the rare governance text that reads like a thriller, which is why your whole board will actually finish it.
What the book argues
The first argument is that the fraud was structural before it was personal. Holmes controlled Theranos through supervoting shares - at the end, roughly 99 percent of voting power - so the board could advise but never compel. Carreyrou shows the consequence in motion: when directors briefly moved to replace her as CEO in 2008, she talked them around in hours, and the moment passed into legend inside the company as proof she was untouchable. Every subsequent control - audits, expert review, even a functioning CFO after the first one was fired for raising concerns - was optional, and the option was never exercised.
The second argument is that information architecture was the fraud's engine. Theranos siloed hardware from software from chemistry, forbade employees to discuss work across teams, and wrapped everything in NDAs enforced by the most feared law firm in America. No single employee could assemble the whole picture - that the Edison device ran a fraction of advertised tests, that most samples ran on modified commercial analyzers, that validation data was cherry-picked. The silence was not cultural accident but designed: Carreyrou documents threats, surveillance, and litigation against those who connected the dots, including the grandson of a board member.
The third argument is about the enablers: social proof substituted for diligence at every gate. Walgreens launched patient testing without ever validating the devices - its own consultant's warnings were overridden for fear a rival chain would get the deal. Investors wired nine figures without audited financials. The board of luminaries lent credibility they never verified, and media amplified the story because other famous people already believed it. The real diligence, the book shows, was done by a reporter, two twenty-something whistleblowers, and a pathologist blogger - people who checked primary evidence against claims. That is the whole lesson: someone must always be doing that job, and title is no evidence anyone is.
Key ideas, translated to your desk
Prestige is not oversight
A board's value is domain expertise plus the power and will to act. Audit yours for both; celebrated names with neither are risk, not protection.
Silos plus NDAs equal unauditable
When no employee may see the whole picture, neither can the board. Treat extreme internal secrecy as a red flag in any company you govern, fund, or partner with.
Verify claims against primary evidence
Walgreens skipped device validation; investors skipped audited financials. Whatever the hurry, the test is simple: has anyone independent actually watched the product do what the deck says?
Use it at work
- Check voting structure before joining any board or funding any company: if founders cannot be overruled, write down what your oversight is actually worth.
- Require audited financials and independent technical validation as conditions of major partnerships and investments - no demo substitutes.
- Build a protected whistleblower channel that reaches the board without passing through management or counsel.
- Run the 'assemble the whole picture' test on your own company: could one competent reviewer trace a flagship claim to primary evidence inside a week?
Read it if
- You serve on boards, invest, or approve partnerships and want failure mechanics in forensic detail.
- You are building a company and want the anti-playbook for culture and controls.
- You want one governance book your entire board will read voluntarily.
You can skip it if
- You already followed the Theranos trials closely and want new material - read Dear Chairman for breadth instead.
- You want prescriptive frameworks; the lessons here arrive as narrative and need your own extraction.
- Medical-industry specifics feel remote from your sector - though the control failures are sector-agnostic.
This book appears in
Curated Tasting Menus that chain this title into a reading route.
Discover more from Kurums | Business Intelligence
Subscribe to get the latest posts sent to your email.
